Le Lézard
Classified in: Health, Business
Subject: DIVIDENDS

Extendicare Announces January 2017 Dividend of C$0.04 per Share


MARKHAM, ON--(Marketwired - January 16, 2017) - Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the "Common Share") for the month of January 2017, which is payable on February 15, 2017 to shareholders of record at the close of business on January 31, 2017. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada).

Extendicare has a Dividend Reinvestment Plan (the "DRIP"), which provides Canadian resident holders of Common Shares with the opportunity to increase their respective investments at a 3% discount to the volume weighted average trading price of the Common Shares on the TSX for the five trading days immediately preceding the dividend payment date. A copy of the DRIP package is available under the investors section of Extendicare's website.

ABOUT EXTENDICARE

Extendicare is a leading provider of care and services for seniors throughout Canada. Through our network of 119 operated senior care and living centres (64 owned/55 managed), as well as our home health care operations, we are committed to delivering care throughout the health care continuum to meet the needs of a growing seniors' population in Canada. Our qualified and highly trained workforce of 23,800 individuals is dedicated to helping people live better through a commitment to quality service and a passion for what we do.

Forward-looking Statements

Information provided by Extendicare from time to time, including this release, contains or may contain forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation, statements regarding its business operations, business strategy, and financial condition. Forward-looking statements can be identified because they generally contain the words "anticipate", "believe", "estimate", "expect", "intend", "objective", "plan", "project", "will" or other similar expressions or the negative thereof. Forward-looking statements reflect management's beliefs and assumptions and are based on information currently available, and Extendicare assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Extendicare to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare's forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare with the securities regulatory authorities, available at www.sedar.com and on Extendicare's website at www.extendicare.com.


These press releases may also interest you

at 06:05
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in...

at 06:05
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it has...

at 06:05
According to the WHO some 50 million people globally suffer from dementia (including Alzheimer's disease) with undiagnosed cases likely doubling these estimates. The numbers are projected to more than triple as access to quality healthcare along with...

at 06:05
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it has...

at 06:00
OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in...

at 06:00
The Association québécoise des pharmaciens propriétaires (AQPP) has filed an application with the Québec Superior Court for authorization to institute a class action lawsuit against ten of its pharmacist members who are owners of six pharmacies, as...



News published on and distributed by: